MedicineNews.net - Medical Updates

EMA: use of Lagevrio based on Molnupiravir for the treatment of COVID-19

EMA’s human medicines Committee ( CHMP ) has issued advice on the use of Lagevrio ( Molnupiravir ) for the treatment of COVID-19. The medicine can be used to treat adults with COVID-19 who do not re ... read article

Paxlovid, a novel COVID-19 oral antiviral treatment candidate has reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study

Pfizer has announced its investigational novel COVID-19 oral antiviral candidate, Paxlovid, has significantly reduced hospitalization and death, based on an interim analysis of the phase 2/3 EPIC-HR ( ... read article

Polatuzumab vedotin plus R-CHP is the first regimen in 20 years to significantly improve outcomes in patients with previously untreated diffuse large B-cell lymphoma compared to standard of care

The pivotal phase III POLARIX trial investigating Polatuzumab vedotin ( Polivy ) in combination with Rituximab ( MabThera / Rituxan ) plus Cyclophosphamide, Doxorubicin and Prednisone ( R-CHP ) versu ... read article

Longer median overall survival in postmenopausal HR+ / HER2- metastatic breast cancer patients treated with Ribociclib

Updated median overall survival ( OS ) results for Ribociclib ( Kisqali ) in combination with Fulvestrant ( Faslodex ) in postmenopausal women with hormone receptor positive, human epidermal growth fa ... read article

Pirfenidone reduces scar tissue in patients with heart failure and preserved ejection fraction

Patients with heart failure with preserved ejection fraction who took the antifibrotic drug Pirfenidone ( Esbriet ) saw a significant reduction in a marker of heart muscle scarring compared with patie ... read article

Anti-LAG-3 antibody Relatlimab and Nivolumab in patients with previously untreated metastatic or unresectable melanoma: RELATIVITY-047 trial has met primary endpoint of progression-free survival

Primary results from the phase 2/3 RELATIVITY-047 trial evaluating the fixed-dose combination of Relatlimab, an anti-LAG-3 antibody, and Nivolumab ( Opdivo ) versus Nivolumab alone in patients with pr ... read article

Nivolumab plus chemotherapy and Nivolumab plus Ipilimumab have demonstrated superior survival benefit compared to chemotherapy in unresectable advanced or metastatic esophageal squamous cell carcinoma

Results from the phase 3 CheckMate -648 trial evaluating treatment with Nivolumab ( Opdivo ) plus chemotherapy or Nivolumab plus Ipilimumab ( Yervoy ) in patients with unresectable advanced or metasta ... read article

IMpower010: Atezolizumab improves disease-free survival in people with resectable early stage lung cancer compared to best supportive care

The phase III IMpower010 study evaluating Atezolizumab ( Tecentriq ), compared with best supportive care ( BSC ), has met its primary endpoint of disease-free survival ( DFS ) at the interim analysis. ... read article

EV-301 trial: survival advantage of Enfortumab vedotin in patients with previously treated advanced urothelial cancer

Results from the phase 3 EV-301 trial were presented at 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium ( ASCO GU ), and published in The New England Journal of Medicine ( N ... read article

Waldenström's macroglobulinemia: Imbruvica prescribing information updated to include long-term data

The U.S. Food and Drug Administration ( FDA ) has approved the update of the Imbruvica ( Ibrutinib ) Prescribing Information to include efficacy and safety data for the combination of Imbruvica with ... read article

CheckMate -816 trial: Nivolumab plus chemotherapy has shown statistically significant improvement in pathologic complete response as neoadjuvant treatment of resectable non-small cell lung cancer

The phase 3 CheckMate -816 trial met a primary endpoint of pathologic complete response ( pCR ) in resectable non-small cell lung cancer ( NSCLC ). In the trial, significantly more patients treated ... read article

IPATential150 study: Ipatasertib in combination with Abiraterone and Prednisone / Prednisolone met one of its co-primary endpoints in patients with metastatic castration-resistant prostate cancer and PTEN loss

The phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival ( rPFS ) in patients with metastatic castration-resistant prostate cancer ( mCRPC ) and whose tu ... read article

Opdivo plus Yervoy combined with two cycles of chemotherapy as first-line treatment of metastatic non-small cell lung cancer, positive CHMP opinion

The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has recommended approval of Opdivo ( Nivolumab ) plus Yervoy ( Ipilimumab ) with two cycles of Plat ... read article

FDA has granted accelerated approval to Zepzelca for metastatic small cell lung cancer

The FDA ( Food and Drug Administration ) has granted accelerated approval to Zepzelca ( Lurbinectedin ) for adult patients with metastatic small cell lung cancer ( SCLC ) with disease progression on o ... read article

CheckMate -577: Nivolumab as adjuvant therapy for patients with resected esophageal or gastroesophageal junction cancer, has met primary endpoint of disease-free survival

The phase 3 CheckMate -577 trial evaluating Nivolumab ( Opdivo ) as an adjuvant therapy for patients with resected esophageal or gastroesophageal junction ( GEJ ) cancer met its primary endpoint of di ... read article